Traders bought shares of AbbVie Inc (NYSE:ABBV) on weakness during trading hours on Thursday. $265.83 million flowed into the stock on the tick-up and $144.78 million flowed out of the stock on the tick-down, for a money net flow of $121.05 million into the stock. Of all equities tracked, AbbVie had the 12th highest net in-flow for the day. AbbVie traded down ($0.22) for the day and closed at $90.33

Several equities analysts have commented on ABBV shares. BMO Capital Markets reissued a “sell” rating and set a $78.00 target price on shares of AbbVie in a research report on Wednesday, August 22nd. ValuEngine cut shares of AbbVie from a “hold” rating to a “sell” rating in a research report on Friday, October 19th. Bank of America lifted their target price on shares of AbbVie from $105.00 to $107.00 and gave the stock a “buy” rating in a research report on Wednesday, August 22nd. Credit Suisse Group set a $85.00 target price on shares of AbbVie and gave the stock a “hold” rating in a research report on Friday, November 2nd. Finally, Wolfe Research started coverage on shares of AbbVie in a research report on Tuesday, October 23rd. They set an “underperform” rating on the stock. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $103.68.

The company has a debt-to-equity ratio of 8.70, a quick ratio of 1.08 and a current ratio of 1.20. The firm has a market capitalization of $136.21 billion, a P/E ratio of 12.09, a P/E/G ratio of 0.84 and a beta of 1.68.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, November 2nd. The company reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.13. The company had revenue of $8.24 billion for the quarter, compared to analysts’ expectations of $8.23 billion. AbbVie had a net margin of 23.50% and a return on equity of 2,006.63%. AbbVie’s revenue was up 17.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.41 EPS. On average, equities analysts predict that AbbVie Inc will post 7.93 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, February 15th. Investors of record on Tuesday, January 15th will be issued a $1.07 dividend. This represents a $4.28 dividend on an annualized basis and a dividend yield of 4.74%. The ex-dividend date is Monday, January 14th. This is a boost from AbbVie’s previous quarterly dividend of $0.96. AbbVie’s payout ratio is 68.57%.

In related news, EVP Henry O. Gosebruch sold 42,450 shares of AbbVie stock in a transaction that occurred on Thursday, November 29th. The shares were sold at an average price of $90.10, for a total value of $3,824,745.00. Following the sale, the executive vice president now owns 30,350 shares of the company’s stock, valued at approximately $2,734,535. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.07% of the company’s stock.

A number of hedge funds have recently modified their holdings of ABBV. Trust Co. of Vermont raised its holdings in AbbVie by 0.7% during the 2nd quarter. Trust Co. of Vermont now owns 215,371 shares of the company’s stock valued at $19,955,000 after acquiring an additional 1,449 shares during the period. Atlas Brown Inc. raised its holdings in AbbVie by 2.0% during the 2nd quarter. Atlas Brown Inc. now owns 31,200 shares of the company’s stock valued at $302,000 after acquiring an additional 608 shares during the period. First Citizens Bank & Trust Co. raised its holdings in AbbVie by 18.2% during the 2nd quarter. First Citizens Bank & Trust Co. now owns 31,450 shares of the company’s stock valued at $2,913,000 after acquiring an additional 4,842 shares during the period. Vigilant Capital Management LLC grew its position in shares of AbbVie by 0.5% during the 2nd quarter. Vigilant Capital Management LLC now owns 207,098 shares of the company’s stock valued at $19,188,000 after purchasing an additional 931 shares in the last quarter. Finally, Accurate Investment Solutions Inc. grew its position in shares of AbbVie by 2.1% during the 2nd quarter. Accurate Investment Solutions Inc. now owns 45,501 shares of the company’s stock valued at $4,216,000 after purchasing an additional 938 shares in the last quarter. 69.85% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/12/07/traders-buy-abbvie-abbv-on-weakness.html.

About AbbVie (NYSE:ABBV)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.

Featured Article: What impact do institutional investors have on markets?

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.